CA3251194A1 - IBUDILAST INTENDED FOR USE IN THE TREATMENT OF POST-COVID PATHOLOGICAL CONDITIONS - Google Patents

IBUDILAST INTENDED FOR USE IN THE TREATMENT OF POST-COVID PATHOLOGICAL CONDITIONS

Info

Publication number
CA3251194A1
CA3251194A1 CA3251194A CA3251194A CA3251194A1 CA 3251194 A1 CA3251194 A1 CA 3251194A1 CA 3251194 A CA3251194 A CA 3251194A CA 3251194 A CA3251194 A CA 3251194A CA 3251194 A1 CA3251194 A1 CA 3251194A1
Authority
CA
Canada
Prior art keywords
day
ibudilast
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3251194A
Other languages
English (en)
French (fr)
Inventor
Kazuko Matsuda
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CA3251194A1 publication Critical patent/CA3251194A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3251194A 2022-02-01 2023-01-31 IBUDILAST INTENDED FOR USE IN THE TREATMENT OF POST-COVID PATHOLOGICAL CONDITIONS Pending CA3251194A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305483P 2022-02-01 2022-02-01
US63/305,483 2022-02-01
PCT/US2023/011931 WO2023150093A1 (en) 2022-02-01 2023-01-31 Ibudilast for use in the treatment of post-covid conditions

Publications (1)

Publication Number Publication Date
CA3251194A1 true CA3251194A1 (en) 2023-08-10

Family

ID=85382992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3251194A Pending CA3251194A1 (en) 2022-02-01 2023-01-31 IBUDILAST INTENDED FOR USE IN THE TREATMENT OF POST-COVID PATHOLOGICAL CONDITIONS

Country Status (6)

Country Link
US (1) US12171752B2 (OSRAM)
EP (1) EP4472631A1 (OSRAM)
JP (1) JP2025504984A (OSRAM)
CN (1) CN118973574A (OSRAM)
CA (1) CA3251194A1 (OSRAM)
WO (1) WO2023150093A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828003B2 (ja) 1998-08-10 2011-11-30 杏林製薬株式会社 多発性硬化症治療薬
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
EP4132521A1 (en) * 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
GB202005890D0 (en) * 2020-04-22 2020-06-03 Aivivo Ltd New uses
WO2022181219A1 (ja) * 2021-02-24 2022-09-01 国立大学法人九州大学 新興ウイルス感染症治療薬

Also Published As

Publication number Publication date
US12171752B2 (en) 2024-12-24
US20230285367A1 (en) 2023-09-14
CN118973574A (zh) 2024-11-15
EP4472631A1 (en) 2024-12-11
WO2023150093A1 (en) 2023-08-10
JP2025504984A (ja) 2025-02-19

Similar Documents

Publication Publication Date Title
US20250073213A1 (en) Treatment of progressive neurodegenerative disease with ibudilast
JP4954085B2 (ja) 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
US12171752B2 (en) Methods of treating post-COVID condition(s)
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US20090028816A1 (en) Treatment of depression, psychosis, and anxiety
US11865214B2 (en) Ibudilast oral formulations and methods of using same
US12005049B2 (en) Methods of preventing cancer metastasis
US10946071B2 (en) Combination of ibudilast and interferon-beta and methods of using same
JP7430719B2 (ja) イブジラストを用いて眼疾患／障害または損傷を治療する方法
US12042485B2 (en) Methods of minimizing cancer metastasis

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250109

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250109

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250219

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423